Chiltern has acquired Pacific Clinical Research, a pan-Asian CRO based in Singapore. The move allows Chiltern to offer integrated services throughout the Asia-Pacific region and strengthens in particular Chiltern's oncology and anti-infective offerings.
The scandal and its repercussions will be felt deep into Big Pharma’s operations in emerging...
The Obama administration's decision to curb the ability of U.S. corporations to skirt taxes by...
Gilead Sciences says it has reached a deal with several generic drugmakers to produce cheaper versions of its popular, expensive hepatitis C drug Sovaldi for use in developing countries.
China's premier promised Wednesday to open the world's No. 2 economy wider to foreign companies, promising favorable conditions despite a wave of anti-monopoly investigations that business groups say might be aimed at limiting competition.
Foreign companies in China feel increasingly targeted for unfair enforcement of anti-monopoly and other laws and might cut investment if conditions fail to improve, a U.S. business group said Tuesday.
The new facility, which will be the group's second-largest pharmaceutical manufacturing facility worldwide, will focus on the bulk production and packaging of Glucophage®, Concor® and Euthyrox®, Merck Serono's leading brands for the treatment of diabetes, cardiovascular diseases and thyroid disorders, respectively.
Under the terms of the agreement, Amerigen and Menovo will jointly develop products for Amerigen to commercialize in the United States. Menovo will be responsible for manufacturing API and finished product whereas Amerigen will be responsible for clinical, regulatory and commercial activities in the United States.
One of Japan’s leading research institutions, the prestigious Riken Institute, will scale down the center at the heart of a stem-cell research scandal earlier this year.
EMD Millipore Expands Biomanufacturing Sciences and Training Center in Japan and Opens New Location in TokyoAugust 26, 2014 8:14 am | News | Comments
EMD Millipore today announced the opening of a new Biomanufacturing Sciences Training Center (BSTC) facility in Tokyo. The facility is designed to help biopharmaceutical companies develop manufacturing processes and find solutions to processing challenges in collaboration with engineers from EMD Millipore.
Japan said Monday it is ready to provide a Japanese-developed anti-influenza drug as a possible treatment for the rapidly expanding Ebola outbreak. Chief Cabinet Secretary Yoshihide Suga said that Japan can offer favipiravir, developed by a subsidiary of Fujifilm Holdings Corp., at any time at the request of the World Health Organization.
A Briton and an American were sentenced to prison on Friday on charges of illegally trading in the personal details of Chinese citizens after they testified they bought such information to help companies combat fraud.
A British man on trial with his American wife for illegally obtaining and selling private information about Chinese nationals says he buys such information from other consulting companies. Peter William Humphrey made the comments Friday after his trial opened in Shanghai.
New Takeda Pharmaceutical Company President Christophe Weber said recently that Japan's biggest drugmaker will continue efforts to expand its business abroad through acquisitions and will outline a new strategy by the end of the year.
Alvogen announced today that it has acquired Dream Pharma in South Korea for $187 million in cash. Dream will be acquired through Alvogen’s Asian subsidiaries and, on completion, will create one of the largest generic pharmaceutical companies in South Korea.
Chinese regulators have launched a series of anti-monopoly investigations of foreign automakers and technology providers, stepping up pressure on foreign companies that feel increasingly unwelcome in China.
Packaging Coordinators has reached a definitive agreement to acquire Penn Pharmaceutical Services Limited. Penn Pharma is headquartered in Tredegar, Wales in the United Kingdom and operates regional offices in New Hope, Pennsylvania and Tokyo, Japan.
With some 100 million people infected with forms of hepatitis, China is the world’s epicenter for the illness.
Impax Laboratories announced that the FDA performed a general GMP inspection and a Pre-Approval Inspection for RYTARY at the company's Taiwan manufacturing facility from July 21 to July 26, 2014. At the conclusion of the inspection, the FDA issued a Form 483 with ten inspectional observations.
A Shanghai court says American and British investigators who worked for drug maker GlaxoSmithKline will stand trial Aug. 8 on charges of illegally obtaining information on Chinese citizens. The Shanghai No. 1 Intermediate People's Court said Tuesday that Yingzeng Yu and her husband Peter Humphrey will have a "public trial."
Staking out a populist stand ahead of the midterm elections, President Barack Obama on Thursday demanded "economic patriotism" from U.S. corporations that use legal means to avoid U.S. taxes through overseas mergers.
A nine-day quarantine imposed on parts of a northern Chinese city where a man died of bubonic plague has been lifted, China's official news agency reported Thursday.
In June 2012, West signed a 99-year lease on 72,800 square meters (approximately 783,600 square feet) of land in Sri City. Sri City offers the advantages of a metropolitan location and was selected primarily on the suitability of land, availability of utilities, labor suitability, logistics and quality of life.
Chinese authorities formally indicted two corporate investigators, an American and Briton, for allegedly illegally obtaining and selling private information, state media reported Monday. Prosecutors in Shanghai filed charges against British investigator Peter Humphrey and his wife Yingzeng Yu, a U.S. citizen, at the city's No. 1 Intermediate People's Court, the official Xinhua News Agency said.
ScinoPharm announced that after 17 years of dedicated service, its co-founder and President & CEO Dr. Jo Shen is retiring at the end of July 2014 and will be succeeded by Dr. Yung-Fa (Fred) Chen, currently Sr. Vice President of R&D and Chief Technology Officer, effective August 1, 2014.
Incyte Corporation announced today that it has earned a $25 million milestone payment from Novartis in connection with the approval of Jakavi® (ruxolitinib) in Japan for the treatment of patients with myelofibrosis.
Hospira has completed the acquisition of an active pharmaceutical ingredient (API) manufacturing facility and an associated research and development (R&D) facility from Orchid Chemicals & Pharmaceuticals Ltd., an Indian pharmaceuticals company, for approximately $218 million, after settling prior advances of approximately $30 million.
Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hepatitis C Treatment, Daklinza® and Sunvepra® Dual RegimenJuly 7, 2014 8:19 am | News | Comments
Bristol-Myers Squibb Company has announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Daklinza® (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor ( in vitro ), and Sunvepra® (asunaprevir), a NS3/4A protease inhibitor, providing a new treatment that can lead to cure for many patients in Japan who currently have no treatment options.
- Page 1